Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for SNDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 89.15M
March 31, 2026 88.54M
December 31, 2025 87.41M
September 30, 2025 86.91M
June 30, 2025 86.06M
March 31, 2025 86.05M
December 31, 2024 85.69M
September 30, 2024 85.57M
June 30, 2024 85.03M
March 31, 2024 84.98M
December 31, 2023 84.83M
September 30, 2023 69.64M
June 30, 2023 69.43M
March 31, 2023 68.50M
December 31, 2022 68.11M
September 30, 2022 60.12M
June 30, 2022 56.40M
March 31, 2022 55.03M
December 31, 2021 54.98M
September 30, 2021 48.85M
June 30, 2021 48.62M
March 31, 2021 48.25M
December 31, 2020 47.88M
September 30, 2020 38.83M
Date Value
June 30, 2020 38.51M
March 31, 2020 30.24M
December 31, 2019 27.14M
September 30, 2019 27.14M
June 30, 2019 27.12M
March 31, 2019 27.10M
December 31, 2018 24.84M
September 30, 2018 24.05M
June 30, 2018 22.71M
March 31, 2018 24.70M
December 31, 2017 24.39M
September 30, 2017 22.31M
June 30, 2017 22.22M
March 31, 2017 18.24M
December 31, 2016 18.22M
September 30, 2016 18.18M
June 30, 2016 17.77M
March 31, 2016 17.77M
September 30, 2014 0.0732M
June 30, 2014 7.881M
March 31, 2014 96.93M
December 31, 2013 42.19M
September 30, 2013 0.62M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Viking Therapeutics, Inc. 116.65M
Kura Oncology, Inc. 88.95M
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
Anika Therapeutics, Inc. 13.38M